基于人群的筛查试验ROSE中抗骨质疏松药物长期依从性及其决定因素
在ROSE随机试验中,24,229名女性被纳入,筛查组FRAX≥15%者受邀行DXA并按国家指南接受抗骨质疏松药物治疗。制动、合并症和合并用药是短期和长期停药的关键决定因素。
要点
- 已启动治疗者5年持续率筛查组与对照组相似(51-52%),一般人群为44%。
- 制动、合并症和合并用药是短期和长期停药的关键决定因素。
核心结论
- ROSE筛查项目显著增加了绝经后女性的治疗启动。
- 筛查女性一旦开始用药,其治疗依从性水平与未筛查者相似。
- 虚弱女性更易停药,凸显对该亚组提供针对性支持的必要。
研究设计与样本
- 2010/2011年,丹麦南部地区65-80岁女性(N=34,229)被邀请参加风险分层骨质疏松策略评估(ROSE)随机研究。
- 筛查组中10年骨折风险中至高(FRAX®≥15%)的女性受邀行双能X线吸收测定法,并按国家指南接受AOM治疗。
- 比较筛查组、对照组和年龄匹配的一般人群样本的AOM依从性,使用10年随访的处方和医院记录数据。
主要发现
- 在FRAX≥15%的ROSE参与者中,5864名筛查组和5790名对照组符合分析条件,另取等量一般人群样本。
- 以药物持有率评估的实施依从性无差异。
- 5年持续率筛查组与对照组相似(51-52%),一般人群较低(44%)。
- FRAX危险因素部分影响筛查组的AOM启动,其他组模式不同;制动、合并症和合并用药是短期和长期停药的关键决定因素。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Screening initiatives for osteoporosis must facilitate treatment of those at elevated fracture risk. In a randomized controlled trial of 24,229 women, those in the screening group with FRAX ≥ 15% were invited for DXA with AOM treatment offered as per national guidelines. Treatment initiation in the following year was 9.5 times higher compared with controls. PURPOSE: To determine if screened individuals have lower adherence to anti-osteoporotic medication (AOM) than unscreened and to examine determinants for low treatment adherence. METHOD: In 2010/2011, women aged 65-80 (N = 34,229) in the Region of Southern Denmark were invited to the risk-stratified osteoporosis strategy evaluation (ROSE) randomized study. Women in the screening group with moderate to high 10-year fracture risk (FRAX® ≥ 15%) were invited for dual-energy x-ray absorptiometry with AOM treatment as per national guidelines. Screened, controls, and an age-matched general population sample were compared for adherence to AOM using 10-year follow-up data on prescription and hospital records. RESULTS: Among ROSE participants with FRAX ≥ 15%, 5864 screened and 5790 controls were eligible for analysis, along with an equal number from the general population. AOM initiation in the first year was 9.5 times higher in screened compared to controls (HR 9.50, 7.16; 12.61). There was no difference in implementation assessed as medication possession ratio. The 5-year persistence rates were similar in screened and controls (51-52%), but lower in the general population (44%). FRAX risk factors partly influenced AOM initiation in the screened, with different patterns in other groups. Immobilization, comorbidities, and co-medications were key determinants of discontinuation in both the short and long term. CONCLUSION: The ROSE screening programme significantly increased treatment initiation in postmenopausal women. Screened women showed similar treatment adherence levels to non-screened once they started medication. However, frail women were more prone to treatment discontinuation, highlighting the need for targeted support in this subgroup. TRIAL REGISTRATION: The original ROSE trial is registered at ClinicalTrials.gov (NCT01388244). The study protocol has been published in Rubin et al. The risk-stratified osteoporosis strategy evaluation study (ROSE): a randomized prospective population-based study. Design and baseline characteristics. Calcif Tissue Int. 2015;96(2):167-79.
引用
- Petersen TG, Rubin KH, Javaid MK, et al. Long-term adherence to anti-osteoporosis medication and determinants of adherence in the population-based screening trial ROSE. Osteoporos Int. 2025. PMID: 39992408. doi:10.1007/s00198-025-07436-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。